Pharmacoeconomic analysis of the treatment of rheumatoid arthritis with Leflunomide in comparison with the combination of Infliximab and Methotrexate

Journal of Medical Economics

Volumn 4, Issue 19-34, 2001, Pages 19-34

  Rubio Terres C ^a   Dominguez Gil A ^a  

^a Aventis Pharma   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; AMOXICILLIN; ASTEMIZOLE; CIPROFLOXACIN; CORTICOSTEROID; ENALAPRIL; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADULT; AGED; ARTICLE; COST; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ECONOMIC ASPECT; FEMALE; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; SPAIN; TREATMENT OUTCOME;

EID: 0035056784     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200104019034     Document Type: Article

References (56)

1. El coste anual de la artritis reumatoide
2. Las enfermedades del aparato locomotor en España, Magnitud y recursos humanos especializados
3. Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: A literature review
4. Biological license application supplement special approvals
5. Pharmacoeconomic models in disease management. A guide for the novice or the perplexed
6. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
7. American College of Rheumatology preliminary definitions of improvement in rheumatoid arthritis
8. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?
9. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation
10. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): A decision analysis model
11. The costs of rheumatoid arthritis: Absolute, incremental, and marginal estimates
12. Direct and indirect costs incurred by Canadian patients with rheumatoid arthritis: A 12 year study
13. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls
14. Direct cost of rheumatoid arthritis during the first six years: A cost-of-illness study
15. Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis
16. Leflunomide: A new modifying drug for rheumatoid arthritis
17. Infliximab and methotrexate in the treatment of rheumatoid arthritis
18. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis
19. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
20. Leflunomide vs sulfasalazine in rheumatoid arthritis: 24-Month update of a randomised, double-blind study
21. Efficacy and safety of leflunomide vs methotrexate in rheumatoid arthritis (RA) results of a double-blind, randomized, 2-year trial
22. Two-year treatment of active rheumatoid arthritis (RA) with leflunomide (LEF) compared with placebo (PL) or methotrexate (MTX)
23. Consenso sobre el diseño de un modelo farmacoeconómico útil para la valoración de antibióticos parenterales de uso hospitalario
24. Guidelines for the management of rheumatoid arthritis
25. Rheumatoid arthritis. Designing and implementing a treatment plan
26. Should methotrexate be a firstline treatment for rheumatoid arthritis?
27. Management of adverse effects of disease-modifying antirheumatic drugs
28. Comparison of different dosing regimens of leflunomide in the treatment of active rheumatoid arthritis (RA)
29. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study
30. Comparative study of the clinical efficacy of four DMARDs (leflunomide, methotrexate, cyclosporine, and levamisole) in patients with rheumatoid arthritis
31. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a
32. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis
33. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis
34. Long-term control of signs and symptoms of rheumatoid arthritis with chimeric monoclonal anti-TNFa antibody (infliximab) in patients with active disease on methotrexate
35. Pharmacoeconomic analysis in new drug development: A pragmatic approach to efficiency studies
36. Budgetary impact analysis for use in reimbursement process of etanercept in moderate to severe rheumatoid arthritis
37. Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatic arthritis story
38. Function and health-related quality of life. Results from a randomized controlled trial of Leflunomide versus Methotrexate or Placebo in patients with active rheumatoid arthritis